Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Structure Therapeutics (GPCR) Gains from Sales and Divestitures (2023 - 2025)

Quarterly Gains from Sales and Divestitures rose 4300.0% to $308000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $308000.0 through Dec 2025, up 4300.0% year-over-year, with the annual reading at $308000.0 for FY2025, 4300.0% up from the prior year.

Structure Therapeutics' Gains from Sales and Divestitures history spans 3 years, with the latest figure at $308000.0 for Q4 2025.

  • Gains from Sales and Divestitures came in at $308000.0 for Q4 2025, up from $7000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $327000.0 in Q2 2023 to a low of $7000.0 in Q4 2024.
  • The 3-year median for Gains from Sales and Divestitures is $317500.0 (2023), against an average of $256833.3.
  • Year-over-year, Gains from Sales and Divestitures tumbled 97.86% in 2024 and then surged 4300.0% in 2025.
  • Structure Therapeutics' Gains from Sales and Divestitures stood at $327000.0 in 2023, then crashed by 97.86% to $7000.0 in 2024, then soared by 4300.0% to $308000.0 in 2025.
  • Per Business Quant, the three most recent readings for GPCR's Gains from Sales and Divestitures are $308000.0 (Q4 2025), $7000.0 (Q4 2024), and $327000.0 (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Structure Therapeutics 8.43 Bn 8.43 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 308,000.00
Dec 31, 2025 308,000.00
Dec 31, 2024 7,000.00
Dec 31, 2024 7,000.00
Dec 31, 2023 327,000.00
Dec 31, 2023 327,000.00
Sep 30, 2023 327,000.00
Sep 30, 2023 327,000.00
Jun 30, 2023 327,000.00
Jun 30, 2023 327,000.00
Mar 31, 2023 245,000.00
Mar 31, 2023 245,000.00